Merck Pharmaceutical Manufacturing (Jiangsu) Co., Ltd.

Primary objective: To evaluate the BE between levothyroxine sodium tablets (test product) produced by Merck Nantong and levothyroxine sodium tablets (Euthyrox) (reference product) produced by Merck Darmstadt Secondary objectives: To study the pharmacokinetics (PK) of total thyroxine (T4) in serum; To study the PK of total triiodothyronine (T3) in serum; To evaluate the safety and tolerability of a single dose of 600 μg levothyroxine sodium

Primary objective: To evaluate the bioequivalence of 5 mg Conxin tablets (test formulation) produced by Merck in Nantong, China, and 5 mg Conxin tablets (reference formulation) produced by Merck in Darmstadt, Germany, after single oral administration in fasting and fed state. Secondary objectives: 1. To evaluate other PK parameters of bisoprolol after single administration of test formulation or reference formulation; 2. To evaluate the safety and tolerability of Conxin after single administration of test formulation and reference formulation.

Primary objectives: 1. To evaluate the bioequivalence of a simplified formulation of Glucophage® extended-release tablets produced by Merck Pharmaceuticals, Jiangsu, China (test formulation) and a simplified formulation of Glucophage® extended-release tablets produced by Merck KGaA, Darmstadt, Germany (reference formulation) after a single oral administration in the fasting state. 2. To evaluate the bioequivalence of a simplified formulation of Glucophage® extended-release tablets produced by Merck KGaA, Jiangsu, China (test formulation) and a simplified formulation of Glucophage® extended-release tablets produced by Merck KGaA, Darmstadt, Germany (reference formulation) after a single oral administration in the fed state. Secondary objectives: 1. To evaluate other PK parameters of the simplified formulation of Glucophage® extended-release tablets after a single administration of the test formulation and the reference formulation. 2. To study the safety and tolerability of the simplified formulation of Glucophage® extended-release tablets after a single administration of the test formulation and the reference formulation.